Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Current Investments (2020 - 2025)

Oncology Institute's Cash & Current Investments history spans 6 years, with the latest figure at $33.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 32.42% year-over-year to $33.6 million; the TTM value through Dec 2025 reached $33.6 million, down 32.42%, while the annual FY2025 figure was $33.6 million, 32.42% down from the prior year.
  • Cash & Current Investments reached $33.6 million in Q4 2025 per TOI's latest filing, up from $27.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $115.2 million in Q4 2021 to a low of $11.5 million in Q3 2021.
  • Average Cash & Current Investments over 5 years is $54.9 million, with a median of $48.5 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: soared 1820.21% in 2021, then plummeted 45.77% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $115.2 million in 2021, then tumbled by 35.92% to $73.8 million in 2022, then grew by 12.26% to $82.9 million in 2023, then tumbled by 40.05% to $49.7 million in 2024, then crashed by 32.42% to $33.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Cash & Current Investments are $33.6 million (Q4 2025), $27.7 million (Q3 2025), and $30.3 million (Q2 2025).